Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

Michelle Petri, William Stohl, Winn Chatham, W. Joseph McCune, Marc Chevrier, Jeff Ryel, Virginia Recta, John Zhong, William Freimuth

Research output: Contribution to journalArticle

Abstract

Objective. To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE). Methods. Two hundred forty-five SLE patients were evaluated prospectively over a 2-year period at 4 centers. Assessments were performed every 3-6 months. Univariate analysis was used to determine the association among the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, serum anti-double-stranded DNA (anti-dsDNA), and plasma BLyS levels. A multivariate repeated-measures model incorporating immunosuppressive therapy was utilized. Results. Ninety-two percent of the patients were female. Sixty-seven percent were white, 31% African American, and 2% Asian (all of these groups may include Hispanic). Mean values at baseline were as follows: age 41.5 years, disease duration 8.1 years, SELENA-SLEDAI 3.3 (median 2, range 0-18), BLyS 5.57 ng/ml, IgG 1,439 mg/dl, C3 104.4 mg/dl, and C4 21.3 mg/dl; among those positive for anti-dsDNA, the median titer was 1:40 (range 1:10-1:1,280). Univariate analysis showed that plasma BLyS levels were associated with anti-dsDNA titers (P = 0.0465) and SELENA-SLEDAI scores (P = 0.0002). In multivariate analyses, a greater increase in the SELENA-SLEDAI score from the previ-ous visit was associated with higher BLyS levels at the previous visit (P = 0.0042) and with a greater increase in the BLyS level from the previous visit (P = 0.0007). Conclusion. The findings of association between a greater increase in the BLyS level from the previous visit and a greater increase in the SELENA-SLEDAI score at the subsequent visit, and between an elevated BLyS level at the previous visit and a greater SELENA-SLEDAI score at the subsequent visit, demonstrate a relationship between circulating BLyS levels and SLE disease activity. These results lend support to the notion that BLyS is a candidate for therapeutic targeting in SLE.

Original languageEnglish (US)
Pages (from-to)2453-2459
Number of pages7
JournalArthritis and Rheumatism
Volume58
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

B-Cell Activating Factor
Systemic Lupus Erythematosus
Estrogens
Safety
Immunosuppressive Agents
DNA
Hispanic Americans
African Americans
Therapeutics
Multivariate Analysis
Immunoglobulin G

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. / Petri, Michelle; Stohl, William; Chatham, Winn; McCune, W. Joseph; Chevrier, Marc; Ryel, Jeff; Recta, Virginia; Zhong, John; Freimuth, William.

In: Arthritis and Rheumatism, Vol. 58, No. 8, 08.2008, p. 2453-2459.

Research output: Contribution to journalArticle

Petri, M, Stohl, W, Chatham, W, McCune, WJ, Chevrier, M, Ryel, J, Recta, V, Zhong, J & Freimuth, W 2008, 'Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus', Arthritis and Rheumatism, vol. 58, no. 8, pp. 2453-2459. https://doi.org/10.1002/art.23678
Petri, Michelle ; Stohl, William ; Chatham, Winn ; McCune, W. Joseph ; Chevrier, Marc ; Ryel, Jeff ; Recta, Virginia ; Zhong, John ; Freimuth, William. / Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. In: Arthritis and Rheumatism. 2008 ; Vol. 58, No. 8. pp. 2453-2459.
@article{bc15d4292a8c4d85957d47c40024d44d,
title = "Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus",
abstract = "Objective. To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE). Methods. Two hundred forty-five SLE patients were evaluated prospectively over a 2-year period at 4 centers. Assessments were performed every 3-6 months. Univariate analysis was used to determine the association among the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, serum anti-double-stranded DNA (anti-dsDNA), and plasma BLyS levels. A multivariate repeated-measures model incorporating immunosuppressive therapy was utilized. Results. Ninety-two percent of the patients were female. Sixty-seven percent were white, 31{\%} African American, and 2{\%} Asian (all of these groups may include Hispanic). Mean values at baseline were as follows: age 41.5 years, disease duration 8.1 years, SELENA-SLEDAI 3.3 (median 2, range 0-18), BLyS 5.57 ng/ml, IgG 1,439 mg/dl, C3 104.4 mg/dl, and C4 21.3 mg/dl; among those positive for anti-dsDNA, the median titer was 1:40 (range 1:10-1:1,280). Univariate analysis showed that plasma BLyS levels were associated with anti-dsDNA titers (P = 0.0465) and SELENA-SLEDAI scores (P = 0.0002). In multivariate analyses, a greater increase in the SELENA-SLEDAI score from the previ-ous visit was associated with higher BLyS levels at the previous visit (P = 0.0042) and with a greater increase in the BLyS level from the previous visit (P = 0.0007). Conclusion. The findings of association between a greater increase in the BLyS level from the previous visit and a greater increase in the SELENA-SLEDAI score at the subsequent visit, and between an elevated BLyS level at the previous visit and a greater SELENA-SLEDAI score at the subsequent visit, demonstrate a relationship between circulating BLyS levels and SLE disease activity. These results lend support to the notion that BLyS is a candidate for therapeutic targeting in SLE.",
author = "Michelle Petri and William Stohl and Winn Chatham and McCune, {W. Joseph} and Marc Chevrier and Jeff Ryel and Virginia Recta and John Zhong and William Freimuth",
year = "2008",
month = "8",
doi = "10.1002/art.23678",
language = "English (US)",
volume = "58",
pages = "2453--2459",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

AU - Petri, Michelle

AU - Stohl, William

AU - Chatham, Winn

AU - McCune, W. Joseph

AU - Chevrier, Marc

AU - Ryel, Jeff

AU - Recta, Virginia

AU - Zhong, John

AU - Freimuth, William

PY - 2008/8

Y1 - 2008/8

N2 - Objective. To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE). Methods. Two hundred forty-five SLE patients were evaluated prospectively over a 2-year period at 4 centers. Assessments were performed every 3-6 months. Univariate analysis was used to determine the association among the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, serum anti-double-stranded DNA (anti-dsDNA), and plasma BLyS levels. A multivariate repeated-measures model incorporating immunosuppressive therapy was utilized. Results. Ninety-two percent of the patients were female. Sixty-seven percent were white, 31% African American, and 2% Asian (all of these groups may include Hispanic). Mean values at baseline were as follows: age 41.5 years, disease duration 8.1 years, SELENA-SLEDAI 3.3 (median 2, range 0-18), BLyS 5.57 ng/ml, IgG 1,439 mg/dl, C3 104.4 mg/dl, and C4 21.3 mg/dl; among those positive for anti-dsDNA, the median titer was 1:40 (range 1:10-1:1,280). Univariate analysis showed that plasma BLyS levels were associated with anti-dsDNA titers (P = 0.0465) and SELENA-SLEDAI scores (P = 0.0002). In multivariate analyses, a greater increase in the SELENA-SLEDAI score from the previ-ous visit was associated with higher BLyS levels at the previous visit (P = 0.0042) and with a greater increase in the BLyS level from the previous visit (P = 0.0007). Conclusion. The findings of association between a greater increase in the BLyS level from the previous visit and a greater increase in the SELENA-SLEDAI score at the subsequent visit, and between an elevated BLyS level at the previous visit and a greater SELENA-SLEDAI score at the subsequent visit, demonstrate a relationship between circulating BLyS levels and SLE disease activity. These results lend support to the notion that BLyS is a candidate for therapeutic targeting in SLE.

AB - Objective. To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE). Methods. Two hundred forty-five SLE patients were evaluated prospectively over a 2-year period at 4 centers. Assessments were performed every 3-6 months. Univariate analysis was used to determine the association among the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, serum anti-double-stranded DNA (anti-dsDNA), and plasma BLyS levels. A multivariate repeated-measures model incorporating immunosuppressive therapy was utilized. Results. Ninety-two percent of the patients were female. Sixty-seven percent were white, 31% African American, and 2% Asian (all of these groups may include Hispanic). Mean values at baseline were as follows: age 41.5 years, disease duration 8.1 years, SELENA-SLEDAI 3.3 (median 2, range 0-18), BLyS 5.57 ng/ml, IgG 1,439 mg/dl, C3 104.4 mg/dl, and C4 21.3 mg/dl; among those positive for anti-dsDNA, the median titer was 1:40 (range 1:10-1:1,280). Univariate analysis showed that plasma BLyS levels were associated with anti-dsDNA titers (P = 0.0465) and SELENA-SLEDAI scores (P = 0.0002). In multivariate analyses, a greater increase in the SELENA-SLEDAI score from the previ-ous visit was associated with higher BLyS levels at the previous visit (P = 0.0042) and with a greater increase in the BLyS level from the previous visit (P = 0.0007). Conclusion. The findings of association between a greater increase in the BLyS level from the previous visit and a greater increase in the SELENA-SLEDAI score at the subsequent visit, and between an elevated BLyS level at the previous visit and a greater SELENA-SLEDAI score at the subsequent visit, demonstrate a relationship between circulating BLyS levels and SLE disease activity. These results lend support to the notion that BLyS is a candidate for therapeutic targeting in SLE.

UR - http://www.scopus.com/inward/record.url?scp=49449092839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449092839&partnerID=8YFLogxK

U2 - 10.1002/art.23678

DO - 10.1002/art.23678

M3 - Article

VL - 58

SP - 2453

EP - 2459

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -